share_log

SciSparc | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SciSparc | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SciSparc | S-8：员工福利计划证券登记
SEC announcement ·  04/02 05:16
牛牛AI助手已提取核心信息
SciSparc Ltd., a biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024, for the purpose of registering 1,013,787 ordinary shares under its 2023 Share Incentive Plan. The Form S-8 registration statement is a necessary step for the company to legally grant stock options and award shares to its employees as part of the incentive plan. The shares will be available for issuance to participants of the plan, which is designed to attract and retain employees and to provide them with a stake in the company's success. The registration statement also includes references to the company's Annual Report and other legal documents that provide additional details about SciSparc's financial and operational status. The company, based in Tel Aviv, Israel, has also made provisions for the indemnification and insurance of its directors and officers, as per Israeli law and its amended and restated articles of association.
SciSparc Ltd., a biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024, for the purpose of registering 1,013,787 ordinary shares under its 2023 Share Incentive Plan. The Form S-8 registration statement is a necessary step for the company to legally grant stock options and award shares to its employees as part of the incentive plan. The shares will be available for issuance to participants of the plan, which is designed to attract and retain employees and to provide them with a stake in the company's success. The registration statement also includes references to the company's Annual Report and other legal documents that provide additional details about SciSparc's financial and operational status. The company, based in Tel Aviv, Israel, has also made provisions for the indemnification and insurance of its directors and officers, as per Israeli law and its amended and restated articles of association.
生物制药公司ScisPARC Ltd. 已于2024年4月1日向美国证券交易委员会（SEC）提交了注册声明，目的是根据其2023年股票激励计划注册1,013,787股普通股。作为激励计划的一部分，S-8表格注册声明是公司合法授予股票期权和向员工奖励股票的必要步骤。这些股票将可供该计划的参与者发行，该计划旨在吸引和留住员工，并为他们提供公司成功的利益。注册声明还包括对公司年度报告和其他法律文件的引用，这些文件提供了有关ScisPARC财务和运营状况的更多详细信息。这家总部位于以色列特拉维夫的公司还根据以色列法律及其经修订和重述的公司章程为其董事和高级职员的赔偿和保险做出了规定。
生物制药公司ScisPARC Ltd. 已于2024年4月1日向美国证券交易委员会（SEC）提交了注册声明，目的是根据其2023年股票激励计划注册1,013,787股普通股。作为激励计划的一部分，S-8表格注册声明是公司合法授予股票期权和向员工奖励股票的必要步骤。这些股票将可供该计划的参与者发行，该计划旨在吸引和留住员工，并为他们提供公司成功的利益。注册声明还包括对公司年度报告和其他法律文件的引用，这些文件提供了有关ScisPARC财务和运营状况的更多详细信息。这家总部位于以色列特拉维夫的公司还根据以色列法律及其经修订和重述的公司章程为其董事和高级职员的赔偿和保险做出了规定。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。